X
[{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals Announces US FDA Grants 67Cu-SARTATE\u2122 Orphan Drug Designation for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals Announces that the US FDA Grants Rare Pediatric Disease Designation to 67Cu-SARTATE to Treat Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals opens SARTATE\u2122 neuroblastoma clinical trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clarity Pharmaceuticals Closes $25m Capital Raising","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Receives US FDA Clearance of IND Application for its Next-Generation PSMA Theranostic Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Commences Cu-64\/Cu-67 SAR-bisPSMA Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Clarity's Cu-64\/Cu-67 SAR-bisPSMA Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Cardinal Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clarity and Cardinal Health Enter into Agreement for Targeted Copper Theranostics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Study May Proceed letter for Clarity\u2019s Cu-64 SAR-bisPSMA trial in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Cohort 2 SARTATE\u2122 Neuroblastoma Therapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial Collaboration for Cu-64 SAR-bisPSMA in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity's US-Based Cu-64 SAR-bisPSMA Trial in Prostate Cancer Opens for Recruitment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated In Clarity's Therapeutic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND Approval From FDA For Theranostic SAR-Bombesin Trial in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Commences COMBAT Theranostic Prostate Cancer Trial in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Treated at the Highest Dose Level in Clarity's Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Treated Using NorthStar Medical Radioisotopes\u2019 Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals\u2019 Phase I\/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Cu-67 SAR-Bombesin in Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity's Theranostic Prostate Cancer Trial Progresses at The Highest Dose Level Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Registrational Phase III CLARIFY Trial in Prostate Cancer Commences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Clarity Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
Under the agreement, NorthStar will be responsible for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials being developed in prostate cancer.
Lead Product(s):
67SAR-bisPSMA
Therapeutic Area: Oncology
Product Name: 67SAR-bisPSMA
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Recipient:
NorthStar Medical Radioisotopes
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
April 10, 2024
Details:
SAR-bisPSMA (64Cu SAR-bisPSMA/67Cu SAR-bisPSMA) are injectable radiolabelled compounds which are being investogated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.
Lead Product(s):
64Cu-SAR-bisPSMA
Therapeutic Area: Oncology
Product Name: SAR-bisPSMA
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 30, 2023
Details:
SAR-bisPSMA (64Cu SAR-bisPSMA/67Cu SAR-bisPSMA) are injectable radiolabelled compounds which are being investogated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.
Lead Product(s):
64Cu-SAR-bisPSMA,67Cu-SAR-bisPSMA
Therapeutic Area: Oncology
Product Name: SAR-bisPSMA
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 30, 2023
Details:
67Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA is the study drug agent that contains copper-67 & 64 and is used to deliver radiation to tumors that express the PSMA protein. It is being evaluated for the treatment of metastatic castrate-resistant prostate cancer.
Lead Product(s):
64Cu-SAR-bisPSMA,67Cu-SAR-bisPSMA
Therapeutic Area: Oncology
Product Name: 64Cu-SAR-bisPSMA
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 29, 2023
Details:
SAR-Bombesin is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).
Lead Product(s):
64Cu-SAR-BBN
Therapeutic Area: Oncology
Product Name: SAR-Bombesin
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 03, 2023
Details:
SARTATE is highly targeted theranostic radiopharmaceutical. It is developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2. SARTATE product can be used with 64Cu for imaging (64Cu SARTATE) or 67Cu for therapy (67Cu SARTATE).
Lead Product(s):
67Cu-Sartate
Therapeutic Area: Oncology
Product Name: 67Cu-Sartate
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
NorthStar Medical Radioisotopes
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 28, 2023
Details:
SAR-Bombesin is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).
Lead Product(s):
67Cu SAR-bisPSMA,64Cu SAR-bisPSMA
Therapeutic Area: Oncology
Product Name: SAR-bisPSMA
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 25, 2023
Details:
SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).
Lead Product(s):
Copper-64 SAR Bombesin,Copper-67 SAR Bombesin
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 20, 2023
Details:
SAR-Bombesin is a highly targeted pan-cancer radiopharmaceutical with broad cancer application. The product utilises Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator.
Lead Product(s):
SAR-bombesin
Therapeutic Area: Oncology
Product Name: SAR-BM
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 21, 2022
Details:
SAR-bisPSMA (64Cu-SAR-bisPSMA) reflects a novel approach of connecting two prostate-specific membrane antigen (PSMA) binding motifs to Clarity's proprietary sarcophagene (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator.
Lead Product(s):
SAR-bisPSMA
Therapeutic Area: Oncology
Product Name: 64Cu-SAR-bisPSMA
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 07, 2022